Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06582810
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-30
Brief Title:
Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage A Prospective Single-Center Observational Cohort Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage Through this prospective analysis we hope to
1 show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderatesevere headache pain following non-traumatic subarachnoid hemorrhage
2 show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage
3 and report vasospasm prevalence in the cohort
Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores on a numeric pain scale every two hours they are awake for a maximum of seven days Monitoring for vasospasm will occur as part of their regular medical care
1 show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderatesevere headache pain following non-traumatic subarachnoid hemorrhage
2 show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage
3 and report vasospasm prevalence in the cohort
Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores on a numeric pain scale every two hours they are awake for a maximum of seven days Monitoring for vasospasm will occur as part of their regular medical care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None